Search

Your search keyword '"Philip, Mary"' showing total 17 results
Start Over Author "Philip, Mary" Journal blood
17 results on '"Philip, Mary"'

1. Dose-Dense Brentuximab Vedotin Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Is Highly Active for Second Line Treatment in Relapsed/Refractory Classical Hodgkin Lymphoma: Final Results of a Phase I/II Study

Author

Lynch, Ryan C., Cassaday, Ryan D., Smith, Stephen D., Fromm, Jonathan R., Cowan, Andrew J., Warren, Edus H., Shadman, Mazyar, Shustov, Andrei R, Till, Brian G., Ujjani, Chaitra S., Libby, Edward, Philip, Mary, Coye, Hilary, Martino, Christen N., Kanan, Sandra, Morris, Karolyn K., Rasmussen, Heather A., Behnia, Sanaz, Nartea, Margaret E., Voutsinas, Jenna M., and Gopal, Ajay K.

Published
2020
Full Text
View/download PDF

3. Safety and Activity of Brentuximab Vedotin (BV) Plus Ifosfamide, Carboplatin, and Etoposide (ICE) for Relapsed/Refractory (Rel/Ref) Classical Hodgkin Lymphoma (cHL): Initial Results of a Phase I/II Trial

Author

Cassaday, Ryan D, primary, Fromm, Jonathan, additional, Cowan, Andrew J., additional, Libby, Edward N., additional, Philip, Mary, additional, Behnia, Sanaz, additional, Nartea, Margaret, additional, Press, Oliver, additional, and Gopal, Ajay K, additional

Published
2016
Full Text
View/download PDF

5. Long Term Follow-up of High-Dose CD20-Targeted Radioimmunotherapy-Based Autologous Transplantation for Patients with Mantle Cell Lymphoma

Author

Cassaday, Ryan D., primary, Stevenson, Philip A., additional, Gooley, Theodore A., additional, Chauncey, Thomas, additional, Pagel, John, additional, Till, Brian G., additional, Philip, Mary, additional, Orozco, Johnnie J., additional, Bensinger, William I., additional, Holmberg, Leona, additional, Shustov, Andrei R., additional, Green, Damian J., additional, Smith, Stephen D., additional, Libby, Edward N., additional, Maloney, David G, additional, Soma, Lorinda A., additional, Press, Oliver W., additional, and Gopal, Ajay K., additional

Published
2014
Full Text
View/download PDF

6. Failure of Intensified Induction Therapy and Inability to Undergo Stem Cell Transplantation Predict Dismal Outcomes in Relapsed/Refractory MYC+ B-Cell Lymphoma

Author

Cassaday, Ryan D., primary, Stevenson, Philip A., additional, Bryant, Bronwyn H., additional, Yeung, Cecilia, additional, Till, Brian G., additional, Smith, Stephen D., additional, Libby, Edward N., additional, Shustov, Andrei R., additional, Pagel, John M., additional, Green, Damian J., additional, Philip, Mary, additional, Orozco, Johnnie J., additional, Fang, Min, additional, Holmberg, Leona, additional, Bensinger, William I., additional, Maloney, David G, additional, Gopal, Ajay K., additional, and Press, Oliver W., additional

Published
2014
Full Text
View/download PDF

7. Rituximab Maintenance Therapy after Autologous Stem Cell Transplantation Improves Survival of Patients with Mantle Cell Lymphoma

Author

Graf, Solomon A., primary, Stevenson, Philip A., additional, Holmberg, Leona A., additional, Till, Brian G., additional, Press, Oliver W., additional, Chauncey, Thomas R., additional, Smith, Stephen D., additional, Philip, Mary, additional, Orozco, Johnnie J., additional, Shustov, Andrei R., additional, Green, Damian J., additional, Libby, Edward N., additional, Bensinger, William I., additional, Pagel, John M., additional, Maloney, David G, additional, Zhou, Yi, additional, Cassaday, Ryan D., additional, and Gopal, Ajay K., additional

Published
2014
Full Text
View/download PDF

8. Full Dose Bendamustine (Treanda ®) Can Be Safely Combined with Rituximab, Etoposide and Carboplatin (TREC): Results of a Phase I Trial in Patients with Relapsed or Refractory Lymphoma

Author

Budde, Lihua Elizabeth, primary, Andrei, Shustov R, additional, Ted, Gooley, additional, Chen, Tara L, additional, Libby, Edward N., additional, Palanca-Wessels, Maria Corinna, additional, Philip, Mary, additional, Martin, Daniel B., additional, Cassaday, Ryan D., additional, Kojouri, Kiarash, additional, Press, Oliver W., additional, and Gopal, Ajay K., additional

Published
2012
Full Text
View/download PDF

15. Radiographic and High-Throughput Sequencing (HTS)-Based Response Assessment after Brentuximab Vedotin (BV) Plus Ifosfamide, Carboplatin, and Etoposide (ICE) for Relapsed/Refractory (Rel/Ref) Classical Hodgkin Lymphoma (cHL): Updated Results of a Phase I/II Trial

Author

Cassaday, Ryan D., Fromm, Jonathan R., Cowan, Andrew J., Smith, Stephen D., Libby, Edward N., Philip, Mary, Nartea, Margaret E., Heye, Christen N., Kanan, Sandra L., Behnia, Sanaz, and Gopal, Ajay K.

Abstract

The likelihood of long-term remission following autologous stem cell transplant (ASCT) for rel/ref cHL is predicted by response to pre-ASCT salvage therapy (Blood 2012;119:1665-70). Salvage regimens incorporating the anti-CD30 antibody-drug conjugate BV, administered sequentially and concurrently with chemotherapy, show promise in improving positron emission tomography (PET)-negative complete remission (CR) rates, transplant eligibility, and outcomes (Lancet Oncol 2015;16:284-92; ASH 2015, #293; ASH 2016, #1109; ASH 2016, #1834). While pre-ASCT PET is a strong predictor of outcome, novel HTS-based assays in development imply greater sensitivity than imaging and a potential role in management and surveillance of lymphomas. Here, we report updated clinical results from our ongoing phase I/II trial (#NCT02227199) in the context of HTS-based detection of HL pre- and post-therapy, as well as circulating cytokine and tumor microenvironment markers.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results